Science Explorer Back to mapMap
Discussion
Researcher · Vanderbilt University · United States

Carlos L. Arteaga

Carlos L. Arteaga publishes mostly in Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, on topics such as HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies and PI3K/AKT/mTOR signaling in cancer.

ORCID 0000-0003-0870-9586 OpenAlex
World rank
#6,518
of 7,710,434 ranked researchers
Rank in United States
#2,249
of 1,627,098
Works
1,326
Citations
56k
Citations per work
42.3
h-index
124
i10-index 393Top 0.1% in Oncology
Carlos L. Arteaga

What does Carlos L. Arteaga research?

Carlos L. Arteaga's work is mostly in Medicine (46%), Biochemistry, Genetics and Molecular Biology (35%).

Health Sciences: 606 works · 45.7% of their workMedicine: 606 works · 45.7% of their workOncology: 349 works · 26.3% of their workPulmonary and Respiratory Medicine: 179 works · 13.5% of their workRadiology, Nuclear Medicine and Imaging: 78 works · 5.9% of their workLife Sciences: 461 works · 34.8% of their workBiochemistry, Genetics and Molecular Biology: 461 works · 34.8% of their workMolecular Biology: 312 works · 23.5% of their workCancer Research: 101 works · 7.6% of their workGenetics: 49 works · 3.7% of their workEverything else: 259 works · 19.5% of their workTHEIR WORKCarlos L. Arteaga1,326works
Life Sciences35%Health Sciences46%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine60645.7%
    1. Biochemistry, Genetics and Molecular Biology46134.8%
  3. Everything else25919.5%
  1. 1Oncology26% of their works
  2. 2Molecular Biology24% of their works
  3. 3Pulmonary and Respiratory Medicine14% of their works
  4. 4Cancer Research8% of their works
  5. 5Radiology, Nuclear Medicine and Imaging6% of their works
  6. 6Genetics4% of their works

Research topics

Which keywords describe Carlos L. Arteaga's research?

The keywords of their largest research topics: Breast Cancer, HER2, Trastuzumab, CDK4/6 Inhibitors, Palbociclib, Targeted Therapy, Tumor Suppression and mTOR.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Breast Cancer3602 topics
  2. HER22141 topic
  3. Trastuzumab2141 topic
  4. CDK4/6 Inhibitors1461 topic
  5. Palbociclib1461 topic
  6. Targeted Therapy1352 topics
  7. Tumor Suppression1322 topics
  8. Signaling1071 topic
  9. mTOR1071 topic
  10. Fc Receptors771 topic
  11. Therapeutic Antibodies771 topic
  12. ALK Inhibitors731 topic
  13. EGFR Mutations731 topic
  14. Cancer Progression721 topic
  15. Smad-dependent pathways721 topic
  16. Cancer Genomics621 topic
  17. Mutational Signatures621 topic
  18. Cell Cycle601 topic
  19. p53601 topic

Where does Carlos L. Arteaga work?

Carlos L. Arteaga's main affiliation in the publication record is Vanderbilt University, United States.

How many publications and citations does Carlos L. Arteaga have?

OpenAlex counts 1,326 works and 56,058 citations for Carlos L. Arteaga, an h-index of 124, ranking #6,518 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Carlos L. Arteaga. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.